Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Key Takeaways Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Here are some of the biggest premarket U.S. stock movers today: Palo Alto Networks (NASDAQ: PANW) stock rose 0.4%, with the ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

O'Reilly Automotive Inc. is suing the three major pharmacy benefit managers in the U.S., as well as the three major insulin manufacturers.